Compare IIIN & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIIN | HQL |
|---|---|---|
| Founded | 1953 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Investment Managers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.9M | 529.4M |
| IPO Year | 1994 | N/A |
| Metric | IIIN | HQL |
|---|---|---|
| Price | $27.46 | $17.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 156.7K | 100.6K |
| Earning Date | 04-16-2026 | 01-01-0001 |
| Dividend Yield | 4.37% | ★ 11.56% |
| EPS Growth | ★ 112.12 | N/A |
| EPS | 0.65 | ★ 0.79 |
| Revenue | ★ $647,706,000.00 | N/A |
| Revenue This Year | $14.20 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | $42.42 | ★ $22.56 |
| Revenue Growth | ★ 22.39 | N/A |
| 52 Week Low | $24.35 | $12.29 |
| 52 Week High | $41.64 | $18.46 |
| Indicator | IIIN | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 51.75 |
| Support Level | $24.42 | $17.01 |
| Resistance Level | $27.53 | $17.80 |
| Average True Range (ATR) | 0.85 | 0.26 |
| MACD | 0.40 | -0.03 |
| Stochastic Oscillator | 82.10 | 51.79 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.